Meeting
2023 ASCO Genitourinary Cancers Symposium
Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC).
Authors
Min Yuen Teo
Memorial Sloan Kettering Cancer Center, New York, NY
Min Yuen Teo , Brendan John Guercio , Eugene J. Pietzak , Maria Ponomarev , Ashley M Regazzi , Colleen Quinlan , David H Aggen , Timothy F. Donahue , Alvin C. Goh , Eugene K. Cha , S. Machele Donat , Guido Dalbagni , Bernard H. Bochner , Samuel A Funt , Dean F. Bajorin , Gopa Iyer , Irina Ostrovnaya , Hikmat A. Al-Ahmadie , Jonathan Coleman , Jonathan E. Rosenberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03520491
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 511)
DOI
10.1200/JCO.2023.41.6_suppl.511
Abstract #
511
Poster Bd #
K15
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results.
First Author: Michal Sternschuss
Poster
2024 ASCO Annual Meeting
Comparing the somatic, germline, and immune landscapes of upper tract urothelial carcinoma (UTUC) and UC of the bladder (UCB).
First Author: Kit L. Yuen
Poster
2022 ASCO Genitourinary Cancers Symposium
Neoadjuvant nivolumab (N) +/- ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).
First Author: Brendan John Guercio
Poster
2022 ASCO Genitourinary Cancers Symposium
Defining hereditary upper tract urothelial carcinoma: Implications for genetic testing and clinical management.
First Author: Hong Truong